Solu Therapeutics Funding: $72M Raised, Series A (2025)
Solu Therapeutics is a Biotech company based in Boston, Massachusetts. It has raised $72M in total funding. Latest round: Series A.
Solu Therapeutics funding overview
Solu Therapeutics is a Biotech company based in Boston, Massachusetts. Solu Therapeutics has raised $72M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in April 2025. The round record for Solu Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include Longwood, Santé··Ventures, DCVC Bio, Astellas Venture Management, Alexandria Venture Investments, Lilly and 1 others. 7 distinct backers are named across the disclosed rounds.
Solu Therapeutics has raised $72M in total disclosed funding across the rounds on record.
Who has invested in Solu Therapeutics?
Longwood, Santé··Ventures, DCVC Bio, Astellas Venture Management, Alexandria Venture Investments, Lilly are named among the investors backing Solu Therapeutics.
What was the latest Solu Therapeutics funding round?
The most recent disclosed round is a Series A, announced in April 2025.
Where is Solu Therapeutics based?
Solu Therapeutics is based in Boston, Massachusetts.
What sector does Solu Therapeutics operate in?
Solu Therapeutics is tracked under Biotech from Boston, Massachusetts, with $72M in disclosed funding.
When did Solu Therapeutics last raise?
The last disclosed Solu Therapeutics round closed in April 2025 at Series A.
We update the Solu Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in Boston and their backers are listed below.
